BRIEF-Bioporto Q1 EBIT loss widens to DKK 4.4 million crowns

<span id="midArticle_start"/>May 5 (Reuters) - Bioporto A/S :

<span id="midArticle_0"/>* Sales of The NGAL Test(TM) increased by 68 pct comparedwith Q1 2014

<span id="midArticle_1"/>* BioPorto has completed an accelerated enrolment ofpatients for the clinical trial with The NGAL Test in the USAand expects to submit a 510(k) application to the FDA in thesummer of 2015

<span id="midArticle_2"/>* Q1 revenue of 4.1 million Danish crowns ($610,100.89)versus 4.8 million crowns in year-earlier period

<span id="midArticle_3"/>* Q1 EBIT was a loss of 4.4 million crowns versus loss of3.6 million crowns in year-earlier period

<span id="midArticle_4"/>* Guidance for 2015 maintained

<span id="midArticle_5"/>* Revenue is expected to be 22 million - 25 million crownsin 2015, representing an increase of approximately 15-35 pct on2014

<span id="midArticle_6"/>* Q1 EBIT for 2015 is forecast at loss between 10 millionand 12 million crowns, and we expect net loss at the level of 8million to 10 million crowns

<span id="midArticle_7"/>Source text for Eikon:

<span id="midArticle_8"/>Further company coverage: ($1 = 6.7202 Danish crowns) (Gdynia Newsroom)

<span id="midArticle_9"/>

via Smart Health Shop Forum http://ift.tt/1Pktm2P